NCT02304367 2024-05-06Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)Kyowa Kirin Co., Ltd.Phase 2 Completed17 enrolled 66 charts